Meta-analysis of the effectiveness of pentavalent live oral vaccine for the prevention of severe forms of rotavirus gastroenteritis in children

Cover Page


Cite item

Full Text

Abstract

Rotavirus infection is ubiquitously distributed and represents a global public health problem. Some studies showed that vaccination with pentavalent oral live vaccine was effective in prevention of severe forms of rotavirus gastroenteritis among children up to 3 years of age. Previous randomized placebo-controlled studies assessing this issue were repeatedly conducted. However, due to the features of the epidemiology of pediatric rotavirus infection in Russia, a metaanalysis was conducted in the risk group — children under the age of 3 years by administering a full vaccination course for a single vaccine registered in the Russian Federation. A search was performed by two independent reviewers covering 1994 to February 2019, without restrictions on language, in five databases on medical and biological publications: Russian Science Citation Index, PubMed, Web of Science, MEDLINE, Scopus, and in contents of thematic journals and bibliographic lists. The meta-analysis included multicenter randomized controlled trials comparing the efficacy of placebo and completed full vaccination course with pentavalent live oral rotavirus vaccine in children under 3 years of age. The primary endpoint of the study was the incidence of severe gastroenteritis among children according to the Vesikari evaluation system. Data processing and generation of forest-plots to evaluate summarized results were carried out by the RevMan 5.3 free software distributed on the Cochrane Community website. The implementation of the “trim and fill” method was performed by using Stata 14.2 software. The meta-analysis consisted of 7 original publications performed as multicenter randomized, placebo-controlled double-blind studies. In the experimental and control group there were enrolled 19,384 and 19,425 subjects, respectively. Three-dose vaccination protocol markedly reduced a risk of infection with severe rotavirus gastroenteritis in the experimental group compared to control group, the odds ratio was 0.34 [95%, CI 0.19—0.60]. Cluster analysis also confirmed the protective effect of the full vaccination course. Group assessment of the vaccination effectiveness against rotavirus infection in countries of Africa and Southeast Asia showed significant protection, the odds ratio was 0.60 [95%, CI 0.52—0.70]. While evaluating the effectiveness of vaccination against rotavirus infection in Finland, the odds ratio was set at the level of statistical significance and reached 0.07 [95%, CI 0.04—0.11]. Thus, a full vaccination course with pentavalent live oral vaccine against rotavirus infection lowers a risk of developing severe rotavirus gastroenteritis in young children.

About the authors

A. A. Kosova

Ural State Medical University of the Russian Ministry of Health

Author for correspondence.
Email: kosova_anna2003@mail.ru
ORCID iD: 0000-0002-0268-8887

Anna A. Kosova - PhD (Medicine), Associate Professor, Head of the Department of Epidemiology.

620028, Yekaterinburg, Phone: +7 (343) 214-86-69

Russian Federation

E. S. Bashkirova

Ural State Medical University of the Russian Ministry of Health

Email: 55147fiend@gmail.com

Epidemiologist, Department of Epidemiology.

Yekaterinburg

Russian Federation

T. I. Mashin

Ural State Medical University of the Russian Ministry of Health

Email: tihonmashin@gmail.com

Epidemiologist, Department of Epidemiology.

Yekaterinburg

Russian Federation

V. I. Chalapa

Yekaterinburg Research Institute of Viral Infections

Email: neekewa@yandex.ru
ORCID iD: 0000-0001-5823-5257

Epidemiologist.

Yekaterinburg, Russian Federation.

Russian Federation

References

  1. Баранов А.А., Намазова-Баранова Л.С., Таточенко В.К., Вишнева Е.А., Федосеенко М.В., Селимзянова Л.Р., Лобзин Ю.В., Харит С.М., Бехтерева М.К., Брико Н.И., Миндлина А.Я., Кудрявцев В.В., Горелов А.В., Подколзин А.Т., Костинов М.П. Вакцинопрофилактика ротавирусной инфекции у детей: Федеральные клинические рекомендации. М.: ПедиатрЪ, 2016. 40 с.
  2. Государственный реестр лекарственных средств Российской Федерации. [State register of medicinal products of the Russian Federation]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ef8ec329-91e8-4e91-b8df-c8759e2f3d3c&t= (09.07.2019)
  3. Косова А.А., Чалапа В.И. Инфекции, связанные с оказанием медицинской помощи, в стационарах России: опыт мета-анализа заболеваемости// Здоровье населения и среда обитания. 2018. № 12. С. 57—64.
  4. Лукьянова А.М., Бехтерева М.К., Птичникова Н.Н. Клинико-эпидемиологическая характеристика вирусных диарей у детей // Журнал инфектологии. 2014. № 6 (1). С. 60—66. doi: 10.22625/2072-6732-2014-6-1-60-66(In Russ.)]
  5. Омельяновский В.В., Авксентьева М.В., Сура М.В., Хачатрян Г.Р., Федяева В.К. Методические рекомендации по проведению метаанализа. М.: ФГБУ «Центр экспертизы и контроля качества медицинской помощи», 2017. С. 28.
  6. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2017 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2018. 268 c.
  7. План основных мероприятий на 2018—2020 годы в рамках Десятилетия детства: распоряжение правительства Российской Федерации от 6 июля 2018 года № 1375-р. URL: http://www.consultant.ru/document/cons_doc_LAW_301904/119d657dfcd17a434f287c95d3568b3b0e484daa (09.07.2019)
  8. Харит С.М., Бехтерева М.К., Лобзин Ю.В., Рудакова А.В., Подколзин А.Т., Тикунов Н.В. Оценка бремени ротавирусных гастроэнтеритов как обоснование необходимости плановой вакцинации // Медицинский совет. 2017. № 4. С. 73—78. doi: 10.21518/2079-701X-2017-4-73-78(In Russ.)]
  9. Breimana R.F., Zamanb K., Armahc G., Sowd S.O., Anhf D.D., Victorg J.C., Hille D., Ciarlet M., Neuzilg K.M. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine, 2012, no. 30S, pp. A24—A29. doi: 10.1016/j.vaccine.2011.08.124
  10. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med., 2002, vol. 21,pp. 1539—1558. doi: 10.1002/ sim.1186
  11. Iwata S., Nakata S., Ukae S., Koizumi Y., Morita Y., Kuroki H., Tanaka Y., Shizuya T., Schodel F., Brown M.L., Lawrence J. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Hum. Vaccin. Immunother., 2013. vol. 9, iss. 8, pp. 1626—1633. doi: 10.4161/hv.24846
  12. Jonesteller C.L., Burnett E., Yen C., Tate J.E. Effectiveness of rotavirus vaccination: A systematic review of the first decade of global postlicensure data, 2006—2016 (Review). Clin. Infect. Dis., 2017, vol. 65, iss. 5, pp. 840—850. doi: 10.1093/cid/cix369
  13. Karafillakis, E., Hassounah, S., Atchison, C. Effectiveness and impact of rotavirus vaccines in Europe, 2006—2014. Vaccine, 2015, vol. 33, iss. 18, pp. 2097—2107doi: 10.1016/j.vaccine.2015.03.016
  14. Moher D., Liberati A., Tetzlaff J., Altman D.G. The PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Open. Med., 2009, vol. 3, pp. 123—130. doi: 10.1371/journal.pmed.1000097
  15. Rosettie K.L., Vos T., Mokdad A.H., Flaxman A.D., Khalil I., Troeger C., Weaver M.R. Indirect rotavirus vaccine effectiveness for the prevention of rotavirus hospitalization: a systematic review and meta-analysis. Am. J. Trop. Med. Hyg, 2018, vol. 98, iss. 4, pp. 1197-1201. doi: 10.4269/ajtmh.17-0705
  16. Shakerian-Rostami S., Moradi-Lakeh M., Esteghamati A., Mobinizadeh M., Shokraneh F., Babashahi S., Yaghoubi M. The efficacy and safety of rotavirus vaccine in children under the five years of age; systematic review and meta-analysis. J. Isfahan Med. School, 2014, vol. 32, iss. 303, pp. 1605-1622.
  17. Soares-Weiser K., Maclehose H., Ben-Aharon I., Goldberg E., Pitan F., Cunliffe N. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst. Rev., 2010, vol. 5: CD008521. doi: 10.1002/14651858.CD008521.pub3
  18. Sow S.O., Tapia M., Haidara F.C., Ciarlet M., Diallo F., Kodio M., Doumbia M., Dembele R.D., Traore O., Onwuchekwa U.U., Lewis K.D.C., Victor J.C., Steele A.D., Neuzil K.M., Kotloff K.L., Levine M.M. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine, 2012, no. 30S, pp. A71-A78. doi: 10.1016/j.vaccine.2011.11.094
  19. Tapia M.D., Armah G., Breiman R.F., Dallas M.J., Lewis K.D., Sow S.O., Rivers S.B., Levine M.M., Laserson K.F., Feikin D.R., Victor J.C., Ciarlet M., Neuzil K.M., Steele A.D. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine, 2012, no. 30S, pp. A79-A85. doi: 10.1016/j.vaccine.2012.01.022
  20. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. URL: https://training.cochrane.org/handbook (09.07.2019)
  21. Vesikari T., Karvonen A., Ferrante S.A., Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the finnish extension study. Eur. J. Pediatr., 2010, no. 169, pp. 1379-1386. doi: 10.1007/s00431-010-1242-3
  22. Vesikari T., Itzler R., Karvonen A., Korhonen T., Van Damme P., Behre U., Bona G., Gothefors L., Heaton P.M., Dallas M., Goveia M.G. RotaTeq®, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine, 2010, no. 28, pp. 345-351. doi: 10.1016/j.vaccine.2009.10.041
  23. Zaman K., Anh D.D., Victor J.C., Shin S., Yunus Md., Dallas M.J., Podder G., Thiem V.D., Mai L.T.P., Luby S.P., Tho L.H., Coia M.L., Lewis K., Rivers S.B., Sack D.A., Schodel F., Steele A.D., Neuzil K.M., Ciarlet M. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet, 2010, no. 376,pp. 615-623. doi: 10.1016/S0140-6736(10)60755-6

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Kosova A.A., Bashkirova E.S., Mashin T.I., Chalapa V.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies